Nanodisc-based mucosal DIVA vaccine for PRRS virus
September 30, 2020
Investigator: Federico A. Zuckermann
Viral structural components that enable vaccine-induced protective immunity against contemporary high morbidity and high mortality PRRS virus
September 18, 2014
The production of interferon (IFN)- by an animal in response to a viral infection is known to be a principal determinant of the animal’s ability to fight the infection. In addition, this...Immunogenicity and potency of PRRS MLV vaccines with and without interferon-alpha suppressing capacity
March 2, 2009
Interferon (IFN)-alpha is the most important anti-viral substance produced by mammalian cells in response to a viral infection. Accordingly, the production of IFN-alpha by an animal during a viral...A study on the feasibility of using a porcine alveolar macrophage cell line to produce a PRRS modified live virus vaccine
August 14, 2007
The goals of this project was: 1) to determine the feasibility of using an innovative porcine alveolar macrophage cell line, designated ZMAC-1, for the production of a PRRS modified live virus (MLV)...Evaluation of nucleic acid delivery methods for a genetic (DNA) vaccine against PRRS
June 13, 2000
Cellular immune response to inactivated PRRS virus vaccines
September 14, 1999
